Meningioma is the most common primary intracranial tumor. Mostly benign, 20% of cases display an aggressive behavior despite best standard of care. The genetic landscape of meningiomas is divided according to NF2 mutational status. Although about 60% of meningiomas display NF2 mutations, the other share is more heterogenous. Mutations in TRAF7, SMO, v-akt murine thymoma viral oncogene homolog 1 (AKT1), PI3KCA and KLF4 are seen mostly in WHO grade 1 meningiomas.
Molecular alterations in meningioma: prognostic and therapeutic perspectives
Cristina Birzu 1, Matthieu Peyre 2, Felix Sahm 3 4 5Affiliations expand
- PMID: 32890025
- DOI: 10.1097/CCO.0000000000000687
Abstract
Purpose of review: To discuss recent advances in the meningioma biology and their clinical implications.
Recent findings: Meningioma is the most common primary intracranial tumor. Mostly benign, 20% of cases display an aggressive behavior despite best standard of care. The genetic landscape of meningiomas is divided according to NF2 mutational status. Although about 60% of meningiomas display NF2 mutations, the other share is more heterogenous. Mutations in TRAF7, SMO, v-akt murine thymoma viral oncogene homolog 1 (AKT1), PI3KCA and KLF4 are seen mostly in WHO grade 1 meningiomas. In higher grade meningiomas, mutations of the TERT promoter and deletions of CDKN2A/B emerge and have prognostic value. Moreover, mutations in DMD, BAP1 and PBRM1 have recently been discovered and are being further explored. DNA methylation subgroups offer valuable insight into meningioma prognosis and its implementation in clinical setting is under evaluation. Moreover, the study of distinct meningioma populations such as radiation-induced meningioma and progestin-associated meningioma may provide further insight into meningioma oncogenesis and potential therapeutic targets.
Summary: The mutational landscape of meningioma has expanded following the use of the new genetic sequencing approaches. Novel mutations have been characterized and reveal their prognostic and therapeutic applications. This improved understanding of meningioma biology has promising implications for novel treatment strategies.
Similar articles
- Biology and clinical management challenges in meningioma.Mawrin C, Chung C, Preusser M.Am Soc Clin Oncol Educ Book. 2015:e106-15. doi: 10.14694/EdBook_AM.2015.35.e106.PMID: 25993161
- Genetic landscape of meningioma.Yuzawa S, Nishihara H, Tanaka S.Brain Tumor Pathol. 2016 Oct;33(4):237-247. doi: 10.1007/s10014-016-0271-7. Epub 2016 Sep 13.PMID: 27624470 Review.
- Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S.Neuro Oncol. 2016 May;18(5):649-55. doi: 10.1093/neuonc/nov316. Epub 2016 Jan 28.PMID: 26826201 Free PMC article.
- Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.Peyre M, Kalamarides M.Neurochirurgie. 2018 Mar;64(1):22-28. doi: 10.1016/j.neuchi.2014.06.007. Epub 2014 Sep 20.PMID: 25245924 Review.
- Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT.Jungwirth G, Warta R, Beynon C, Sahm F, von Deimling A, Unterberg A, Herold-Mende C, Jungk C.Acta Neuropathol Commun. 2019 Aug 30;7(1):140. doi: 10.1186/s40478-019-0793-4.PMID: 31470906 Free PMC article.
Cited by 1 article
- The Prognostic Value of Methylation Signatures and NF2 Mutations in Atypical Meningiomas.Meta R, Boldt HB, Kristensen BW, Sahm F, Sjursen W, Torp SH.Cancers (Basel). 2021 Mar 12;13(6):1262. doi: 10.3390/cancers13061262.PMID: 33809258 Free PMC article.
References
- Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 2019; 21: (Suppl 5): v1–v100.
